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Conclusions: Dose delivery in breast cancer patients irradiated during 
vmDIBH, as verified in vivo with 2D EPID dosimetry, is as accurate as 
in patients irradiated during FB. 
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Purpose/Objective: The aim of this study was to find out early 
cardiac changes from doxorubicin based chemotherapy and 
radiotherapy in patients with early and locally advanced carcinoma 
breast and to assess cardiac changes in relation to radiation dose 
received by heart. 
Materials and Methods: Investigations like ECG, ECHO and ERV 
(Equilibrium radionuclide ventriculography) were done at baseline, 
after chemotherapy, after radiotherapy and after 6 months of 
followup. Changes in ECG, ECHO and ERV were recorded at different 
time periods during the study. Left ventricular ejection fraction 
(LVEF) was recorded using both ECHO and ERV. In ECHO other 
parameters like Fractional shortening (FS), Mitralvalve E point septal 
separation (MVEPSS) and PEP/LVET ratio (Pre ejectionperiod/Left 
ventricular ejection time) were recorded. Patients were divided into 4 
groups according to the sequence of chemotherapy and radiotherapy. 
Results: The most common ECG change was T wave inversion in the 
pre-cordial leads. One patient had ST depression in V4 & V5 leads and 
2 patients had physiological T wave inversion in Lead III. In Group 1 
mean LVEF (ECHO) at baseline was 66.79 ±3.73. It decreased to 63.45 
± 3.54 after chemotherapy. It further decreased to 61.64 ± 4.26 after 
RT. On follow up there was a further decline to 61.42 ±3.27. In Group 
2 baseline mean LVEF was 66.67 ± 4.33. Post RT it slightlydecreased to 
66 ± 4.975, while post chemotherapyit further declined to 62.7 ± 
2.92.During follow up mean LVEF further decreased to 61.89 ± 2.934. 
In Group 4 baseline mean LVEF was 67.25 ± 4.33, which decreased 
after chemotherapy to 64.75 ± 2.062. During follow up it further 
decreased to 63.25 ± 2.363.  LVEF was also measured by MUGA/ ERV. 
In Group 1 mean LVEF at baseline was 58.14 ±2.997. After 
chemotherapy it decreased to 56.15 ± 3.144. After RT it increased to 
56.21 ± 3.81 and during follow up mean LVEF decreased to 55.21 ± 
2.913. In Group 2 mean LVEF at baseline was 59.11 ± 1.41. Post RT 
decreased to 58.67 ±2.872 and post chemotherapy it decreased to 
54.44 ± 1.81. During follow up it increased to 55.22 ± 1.787. In Group 
4 mean LVEF at baseline was 60 ± 1.63, which decreased to 58.75 ± 
1.89 after chemotherapy. During follow up it further decreased to 
56.25 ± 2.63. 
Conclusions: Our prospective study shows that a significant number of 
patients can develop a transient depression in ventricular function 
after chemotherapy and radiotherapy. ECG changes in our study were 
not specific. T wave inversion was the most common abnormality, 
suggestive of ventricular repolarisation abnormality. Decrease in LVEF 
was seen in our patients both by conventional ECHO and MUGA/ ERV 
scan during different phases of treatment. These changes indicate 
that doxorubicin based chemotherapy and radiotherapy produces 
acute abnormality in left ventricular function. Whether these results 
are predictive of the development of chronic cardiac toxicity can only 
be answered by serially investigating these patients for a longer 
duration. 
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Purpose/Objective: Linear accelerator delivered partial breast 
radiotherapy has a number of advantages over other technologies. 
These include: No new clinical skills, improved efficiency and 
economics, non invasive (vs. brachy), performed with known histology 
(vs. IORT), and ability to deliver accurate and uniform dosimetry. On 
the other hand, uncertainties in target localisation with external 
beam RT has resulted in large PTV expansion margins and increased 
dose to the surrounding normal tissue. This work determines the 
utility of a novel device that allows for accurate localisation and 
patient positioning, facilitating reduced treatment volumes for either 
APBI or breast boost following whole breast RT. 
Materials and Methods: A novel implantable device (BioZorb™ Tissue 
Marker) constructed of standard surgical materials (bio-absorbable 
polymer and Ti clips) has been developed. The polymer is formed into 
a semi-rigid spiral and shaped into a sphere or ellipsoid, with six clips 
strategically placed for visualisation and orientation. A range of sizes 
is available to match the lumpectomy cavity. The implant is placed 
into the cavity at the time of surgery. Several weeks post surgery, 
treatment planning CT (including respiratory gating) is performed. The 
envelope of the implant abutting the margin of the tissue cavity plus 
1cm defines the CTV with an additional 0.5cm expansion for the PTV. 
The treatment is delivered using either 3D conformal or VMAT. Patient 
setup is facilitated with CBCT and a post treatment scan to reveal 
residual error. 
Results: To date 3 patients have been treated using APBI with the 
implant. The average PTV was 84cc compared to 378cc worst case 
using all hyperdense tissue surrounding the cavity, and 788cc for the 
whole breast. The extent of respiratory motion ranged from 0.7 to 
2mm and mean residual error for all measured treatment fractions 
was 1mm (SD 2.3mm). Using a VMAT technique provided further 
enhancement to APBI reducing the non imaging component of 
treatment to 112sec with no floor rotations required and a 36% 
reduction in MU over a non coplanar 3D conformal method. 
 
Conclusions: This novel implantable device provides for greater 
certainty of target definition and assessment of respiratory motion 
when defining the PTV, facilitating the use of IGRT for partial breast 
treatment. Efficient image guided setup further allows for a reduction 
in margin. Post treatment imaging validates the use of a 0.5cm PTV 
expansion. Using this device in the breast parallels the use of other 
fiducially guided treatment sites such as the prostate. When 
positioning the patient, use of the implant serves as a significant 
improvement compared to highly uncertain target surrogates such as 
skin markers or random clips. The device is also able to provide 
certainty of target location in breast boost treatment where there is 
usually limited evidence of the location of the primary site at the 
time of boost.  
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